An Open Clinical Study Exploring the Safety, Tolerability, and Preliminary Efficacy of Human Umbilical Cord Mesenchymal Stem Cell Injection in the Treatment of Interstitial Lung Disease (ILD)
Latest Information Update: 30 May 2025
At a glance
- Drugs Umbilical cord mesenchymal stem cell injection Shanghai Life Science And Technology (Primary)
- Indications Interstitial lung diseases
- Focus Adverse reactions
- Sponsors Shanghai Life Science and Technology
Most Recent Events
- 25 May 2025 Planned primary completion date changed from 1 Oct 2025 to 1 Oct 2027.
- 25 May 2025 Planned initiation date changed from 1 Oct 2024 to 1 Oct 2025.
- 06 Aug 2024 New trial record